Filtering by:
Soft Tissue SarcomaFDA Approves Vitrakvi (Larotrectinib) for Tumors With Certain Genetic Change
For the second time, the US Food and Drug Administration (FDA) has approved a drug to treat tumors with a specific genetic change regardless of the type of cancer. Vitrakvi (larotrectinib) is for adults and children with solid tumors that test positive for NTRK genes, which can help cancerous tumors grow.
Cancer Facts and Figures: Death Rate Down 25% Since 1991
The death rate from cancer in the US has declined steadily over the past 2 decades, according to annual statistics reporting from the American Cancer Society.
FDA Approves Lartruvo for Soft Tissue Sarcoma
The US Food and Drug Administration (FDA) has approved Lartruvo (olaratumab) for advanced soft tissue sarcoma.
FDA Approves Halaven (Eribulin) for Liposarcoma
The US Food and Drug Administration (FDA) has approved the chemotherapy drug Halaven (eribulin) to treat liposarcoma, a type of soft tissue sarcoma.
FDA Approves Yondelis (Trabectedin) for Advanced Soft Tissue Sarcoma
The US Food and Drug Administration (FDA) has approved the chemotherapy drug Yondelis (trabectedin) to treat 2 types of soft tissue sarcomas – liposarcoma and leiomyosarcoma – that have spread to other parts of the body and/or cannot be removed through surgery.